RNA mis-splicing in children with myotonic dystrophy is associated with physical function
Hartman, J. M.; Ikegami, K.; Provenzano, M.; Bates, K.; Butler, A.; Jones, A. S.; Berggren, K. N.; Dekdebrun, J.; McKay, M. J.; Baldwin, J. N.; Cornett, K. M. D.; Burns, J.; Kiefer, M.; Johnson, N. E.; Hale, M. A.; DMCRN,
Show abstract
ObjectivesDysregulated RNA alternative splicing is the hallmark of myotonic dystrophy type 1 (DM1). However, the association between RNA mis-splicing and physical function in children with the most severe form of disease, congenital myotonic dystrophy (CDM), is unknown. Methods82 participants (42 DM1 adults & 40 CDM children) with muscle biopsies and measures of myotonia, motor function, and strength were combined from five observational studies. Data were normalized and correlated with an aggregate measure of alternative splicing dysregulation, [MBNL]inferred in skeletal muscle biopsies. Multiple linear regression analysis was performed to predict [MBNL]inferred using clinical outcome measures alone. Similar analyses were performed to predict 12-month physical function using baseline metrics. ResultsMyotonia (measured via vHOT) was significantly correlated with RNA mis-splicing in our cross-sectional population of all DM1 individuals; CDM participants alone displayed no myotonia despite a similar range of RNA mis-splicing. Measures of motor performance and muscle strength were significantly associated with [MBNL]inferred in our cohort of all DM1 individuals and when assessing CDM children independently. Multiple linear regression analyses yielded two models capable of predicting [MBNL]inferred from select clinical outcome assessments alone in all subjects (adjusted R2 = 0.6723) or exclusively in CDM children (adjusted R2 = 0.5875). InterpretationOur findings establish significant correlations between skeletal muscle performance and a composite measure of alternative splicing dysregulation, [MBNL]inferred, in DM1. The strength of these correlations and the development of the predictive models will assist in designing efficacious clinical trials for individuals with DM1, particularly CDM.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- DOCK3 is a dosage-sensitive regulator of skeletal muscle and Duchenne muscular dystrophy-associated pathologies. 93%
- Loss of adenylosuccinate synthetase 1 in mice recapitulates features of ADSS1 myopathy 93%
- Mouse models of NADK2 deficiency analyzed for metabolic and gene expression changes to elucidate pathophysiology 93%
Similar papers in this journal
- Mutations in MYLPF cause a novel segmental amyoplasia that manifests as distal arthrogryposis 94%
- High-throughput splicing assays identify missense and silent splice-disruptive POU1F1 variants underlying pituitary hormone deficiency 92%
- MRSD: a novel quantitative approach for assessing suitability of RNA-seq in the clinical investigation of mis-splicing in Mendelian disease 92%
Similar papers in this journal
- The Australian Genomics Mitochondrial Flagship: A National Program Delivering Mitochondrial Diagnoses 93%
- Diagnosing missed cases of spinal muscular atrophy in genome, exome, and panel sequencing datasets 93%
- Recognizing the Evolution of Clinical Syndrome Spectrum Progression in Individuals with Single Large-Scale mitochondrial DNA deletion syndromes (SLSMDS) 92%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.